Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584081 | 0.81 | HPGD (0.45) | LMNAGAAHPGDALDH1A1HSD17B10 | |
| SCHEMBL5736393 | 0.68 | DUT (0.34) | — | |
| SCHEMBL3743319 | 0.64 | CYP3A4 (0.37) | ALDH1A1HSD17B10CNR2 | |
| SCHEMBL24915271 | 0.63 | CXCR4 (0.68) | HPGDALDH1A1KDM4EALOX15CXCR4 | |
| SCHEMBL26975134 | 0.62 | SMN1; SMN2 (0.35) | LMNAGAAHPGDALDH1A1KDM4E | |
| SCHEMBL26998850 | 0.62 | TDP1 (0.41) | LMNAALDH1A1L3MBTL1 | |
| SCHEMBL11377645 | 0.62 | DRD2 (0.40) | LMNAGAAHPGDALDH1A1HSD17B10 | |
| SCHEMBL27316051 | 0.61 | DUT (0.33) | — | |
| SCHEMBL6740861 | 0.61 | HRH4 (0.50) | L3MBTL1 | |
| SCHEMBL18641445 | 0.60 | SMN1; SMN2 (0.43) | LMNAGAAALDH1A1ALOX15CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002092577-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |